Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124463 | 0.88 | ELANE (0.63) | ELANECYP2C9NOTUM | |
| SCHEMBL4136626 | 0.83 | ELANE (0.55) | ELANEADRB1HTR1ACYP2C9HRH3 | |
| SCHEMBL4135840 | 0.82 | ELANE (0.52) | ELANEADRB1HTR1ACYP2C9HRH3 | |
| SCHEMBL4123923 | 0.77 | ELANE (0.51) | ELANECYP2C9 | |
| SCHEMBL4126035 | 0.75 | ELANE (0.74) | ELANE | |
| SCHEMBL4128967 | 0.75 | ELANE (0.60) | ELANECYP2C9NOTUM | |
| SCHEMBL4132323 | 0.74 | ELANE (0.71) | ELANE | |
| SCHEMBL4136719 | 0.74 | ELANE (0.58) | ELANECYP2C9NOTUM | |
| SCHEMBL4126909 | 0.74 | ELANE (0.57) | ELANENOTUM | |
| SCHEMBL4132268 | 0.73 | ELANE (0.70) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | claimed |
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | SERPINB1, ELANE, MPO | ELANE 2/4885ADRB1 916/4885HTR1A 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.